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MUTYH variants are differently distributed in geographical areas of the world. In MUTYH-associated polyposis (MAP) patients
from North-Eastern Italy, c.93313A>C (IVS1013A>C), a transversion causing an aberrant splicing process, accounts for nearly
1/5 of all mutations. The aim of this study was to verify whether its high frequency in North-Eastern Italy is due to a founder
effect and to clarify its impact on MUTYH transcripts and protein. Haplotype analysis and age estimate performed on members
of eleven Italian MAP families and cancer-free controls provided evidence that c.93313A>C is a founder mutation originated
about 83 generations ago. In addition, the Italian haplotype associated with the c.93313A>C was also found in German
families segregating the same mutation, indicating it had a common origin in Western Europe. Altogether c.93313A>C and
the two common Caucasian mutations p.Tyr179Cys and p.Gly396Asp represent about 60% of MUTYH alterations in MAP
patients from North-Eastern Italy, suggesting the opportunity to perform targeted molecular screening for these variants in the
diagnostic setting. Expression analyses performed on lymphoblastoid cell lines supported the notion that MUTYH c.93313A>C
alters splicing causing the synthesis of a non functional protein. However, some primary transcripts escape aberrant splicing,
producing traces of full-length transcript and wild-type protein in a homozygote; this is in agreement with clinical findings
that suggest a relatively mild phenotypic effect for this mutation. Overall, these data, that demonstrate a founder effect and
further elucidate the splicing alterations caused by the MUTYH c.93313A>C mutation, have important implications for genetic
counseling and molecular diagnosis of MAP.
Introduction
It is estimated that 5% of colorectal cancer (CRC) cases can
be explained by inherited CRC syndromes.1 Several tumor
suppressor genes (e.g., APC, TP53 and CDKN2A), proto-
oncogenes (e.g., KRAS) and DNA repair genes2 are involved
in CRC carcinogenesis. The latter includes genes of the mis-
match repair system and MUTYH, a gene belonging to the
base excision repair system.
MUTYH (OMIM 604933) encodes a DNA glycosylase
involved in the repair of 8-oxoguanine (8-oxoG), one of the
typical mutagenic lesions generated by oxidative stress. Since
8-oxoG mispairs with adenine, MUTYH excises the mis-
paired adenine, thus preventing G:C>T:A transversions. Bial-
lelic germline mutations in MUTYH were shown to result in
multiple colorectal adenomas and CRC, likely as a result of
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the accumulation of G>T somatic mutations in APC, KRAS,
and presumably other target genes.3,4
MUTYH-Associated Polyposis (MAP; OMIM 608456) is
an inherited polyposis syndrome with autosomal recessive
transmission, accounting for about 1% of all CRC cases.1 The
significance of monoallelic MUTYH mutations is still
debated; our previous study on Italian patients, as well as
larger case-control studies, provided evidence that the condi-
tion of heterozygosity for MUTYH mutations contributes to
the development of some CRCs.5,6
The distribution of MUTYH mutations shows ethnic differ-
ences.7,8 p.Tyr179Cys (c.536A>G) and p.Gly396Asp
(c.1187G>A) are the most frequent mutations in Caucasians,9
while other population-specific mutations have been reported
in Japan (p.Arg245Cys and c.934-2A>C),10 Portugal
(c.1227_1228dup)11 and Finland (p.Ala473Asp).12 As expected,
in Italy the most common mutations are p.Tyr179Cys and
p.Gly396Asp, associated with classical MAP phenotypes with
some degree of variability. An Italian study found a relatively
high frequency of the c.1437delGGA mutation,13 but its effective
contribution to MAP in our country seems relatively marginal.
We recently detected c.933þ3A>C, a MUTYH mutation
already reported in the Leiden Open Variation Database
(LOVD),14 (http://chromium.liacs.nl/LOVD2/colon_cancer/
home.php?select_db¼MUTYH) in 11 unrelated cases, includ-
ing one homozygote. This splicing variant accounts for about
15% of the MUTYH mutations identified in our cohort of
MAP patients (12 out of 82 mutant alleles), coming mainly
from the North-East of Italy. This finding appears particu-
larly relevant if compared to the frequencies of the most
common p.Tyr179Cys and p.Gly396Asp, each of which
accounted for 22% of mutant alleles on the same series of
cases, a relatively smaller fraction compared with other Euro-
pean regions. Of note, c.933þ3A>C has been reported also
in other populations, but at lower frequencies (1–8%).7,9,15–26
Since these data suggest the possible presence of a founder
effect in the North-Eastern Italian population, we undertook
haplotype analysis to verify this hypothesis. We also investi-
gated in detail the molecular effects of this mutation.
Material and Methods
Cases and controls
Since 2003 we have sequenced the MUTYH gene in 128 APC
mutation-negative patients with polyposis referred to the
Centro di Riferimento Oncologico in Aviano. We found 17
different MUTYH nonpolymorphic variants in 35 cases
(27%). This study was carried out on 11 apparently unrelated
families of probands with the c.933þ3A>C mutation: 1
homozygote, 1 simple heterozygote and 9 compound hetero-
zygotes (Table 1). Ten patients had attenuated polyposis, one
had diffuse polyposis, and seven had developed CRC.
Detailed family histories, including details on geographic ori-
gins were obtained for all patients. Genealogic investigations
did not reveal any relationship between individuals from dif-
ferent families. All patients were resident in North-Eastern
Italy and/or had North-Eastern Italian origin, specifically
from the Veneto and Friuli-Venezia Giulia regions (Fig. 1).
Seventy healthy controls, native from North-Eastern Italy,
were investigated to estimate allele frequencies in the general
population: these included 58 individuals with negative colo-
noscopy (clean colon), and 12 subjects belonging to nuclear
pedigrees without history of CRC (parents from 6 father–
mother–child trios). In addition, 8 noncarrier chromosomes
from healthy relatives belonging to the Italian MAP families
segregating the MUTYH recurrent mutation, were used to
estimate control haplotypes.
DNA samples for haplotype analysis were also collected
from members of 11 German MAP families segregating
c.933þ3A>C, ascertained through two homozygous and 9
compound heterozygous probands.
Overall, 37 individuals (22 probands and 15 relatives)
from Italian and German families segregating the
c.933þ3A>C MUTYH mutation were investigated. One to
three relatives were genotyped in 10 families. In the remain-
ing families, only the index case was available for genotyping.
Samples from two healthy individuals with wild type
(WT) MUTYH genotype were used as controls for mRNA
and protein expression.
Informed consent was obtained from all study partici-
pants. The genetic testing protocol has been evaluated and
approved by the Local Independent Ethical Committee
(CRO-15-1997).
Sample collection and lymphoblastoid cell line
establishment
Lymphocytes were collected from 20 ml of peripheral blood
using LymphoprepTM solution (Axis-Shield, Dundee, Scot-
land) according to manufacturer’s instructions and resus-
pended in 90% FBS, 10% DMSO, frozen at 80C and then
stored in liquid nitrogen. Lymphoblastoid cell lines (LCLs)
were established from one c.933þ3A>C homozygote, four
c.933þ3A>C compound heterozygotes (Table 1), and two
What’s new?
Polyposis-associated variations in the base excision repair gene MUTYH are distributed unevenly across different ethnicities,
suggesting diverse mutation origins and founder effects. This haplotype analysis successfully documented the first MUTYH
founder mutation—a splice variant known as c.93313A>C, frequently detected in polyposis patients from northeastern Italy.
Knowledge of the mutation’s origins in this population could have important implications for genetic counseling and
diagnosis.
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MUTYH WT controls. Lymphocytes from patients and con-
trols were thawed rapidly at 37C and immortalized through
EBV infection in presence of cyclosporin A. LCLs were
grown in RPMI 10% FBS and 1% penicillin-streptomycin at
37C and 5% CO2.
Microsatellite analysis
A set of 11 microsatellite markers spanning a region of 8 Mb
covering the MUTYH locus was investigated. The following
microsatellites, listed in order from telomere to centromere,
were analyzed: D1S2861, D1S211, D1S421, D1S451, D1S2677,
D1S3175, D1S2797, D1S2874, D1S2824, D1S197 and D1S427
(Table 2). PCR primer sequences were designed using Primer
Blast software (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/). Primer sequences and conditions are available on
request. PCR product size determination was evaluated by
capillary electrophoresis on an ABI3100 Sequencer using Gen-
escan 2.1 software (Applied Biosystems, Foster city, CA).
Haplotyping and estimate of mutation age
Haplotypes including microsatellites D1S2861, D1S211,
D1S421, D1S451, D1S2677, D1S3175, D1S2797 and D1S2874
Figure 1. Map of Italy showing the geographic origin (areas in
black) of the families segregating the c.933þ3A>C mutation in
North-Eastern Italy. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
Table 1. Genotypes and clinical characteristics of the families segregating the c.933þ3A>C MUTYH mutation
FAM Case ID Genotype1 Family relationship Phenotype2 LCL3
1 FAP82 c.[536A>G]; c.[933þ3A>C] PROBAND AP; CRC 50 y No
2 FAP117 c.[933þ3A>C]; c.[1437delGGA] PROBAND DP Yes
3 FAP181 c.[933þ3A>C]; c.[1187G>A] PROBAND AP; CRC 39 y Yes
4 FAP278 c.[933þ3A>C]; c.[1147delC] PROBAND AP; CRC 45 y Yes
4 FAP341 c.[933þ3A>C]; [¼] BROTHER – No
4 FAP345 c.[933þ3A>C]; [¼] BROTHER – No
5 FAP294 c.[933þ3A>C]; c.[734G>A] PROBAND AP Yes
6 FAP349 c.[933þ3A>C]; c.[933þ3A>C] PROBAND AP Yes
6 FAP359 c.[933þ3A>C]; [¼] BROTHER – No
7 FAP3524 c.[933þ3A>C]; [¼] PROBAND AP; CRC 45 y No
7 FAP411 WT SON – No
7 FAP412 c.[933þ3A>C]; [¼] SON – No
8 FAP426 c.[933þ3A>C]; c.[536A>G] PROBAND AP; CRC 44 y No
8 FAP536 c.[933þ3A>C]; [¼] SISTER – No
8 FAP537 c.[536A>G]; [¼] BROTHER – No
8 FAP538 c.[933þ3A>C]; [¼] SISTER – No
9 FAP443 c.[933þ3A>C]; c.[421delC] PROBAND AP No
9 FAP446 c.[933þ3A>C]; c.[421delC] SISTER – No
10 CFS167 c.[933þ3A>C]; c.[1147delC] PROBAND AP; CRC 40 y No
10 FAP214 c.[933þ3A>C]; [¼] BROTHER – No
11 CFS443 c.[933þ3A>C]; c.[1437delGGA] PROBAND AP; CRC 54 y No
11 FAP271 c.[1437delGGA]; [¼] SON – No
11 FAP272 c.[1437delGGA]; [¼] SON – No
1GenBank reference sequence MUTYH: NM_001128425.1. 2DP, diffuse polyposis; AP, attenuated polyposis; CRC, colorectal cancer; , no tumor.
3LCL, lymphoblastoid cell line, available (Yes) or not (No). 4A single MUTYH mutation was identified in this proband, who had a typical MAP
phenotype. Presence of an additional undetected mutation cannot be excluded.
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were manually constructed to minimize the number of
recombinations both in Italian and German families.
The DMLEþ2.2 software developed by Rannala and
Reeve27 was used to estimate the age of c.933þ3A>C in
North-Eastern Italy. The program, freely available at URL:
http://www.dmle.org, uses a Bayesian approach to compare
differences in linkage disequilibrium between the mutation
and flanking markers in DNA samples from mutation car-
riers and controls. The software generates the marginal poste-
rior probability density of mutation age based on the follow-
ing parameters: (a) observed haplotypes or genotypes in
normal and affected chromosomes; (b) map distances
between markers and mutation site; (c) population growth
rates and (d) an estimated proportion of the mutation bear-
ing chromosomes sampled.
Map distances were estimated on the basis of the
Marshfield genetic map (URL:http://www.ncbi.nlm.nih.gov/
mapview/) or inferred on the basis of physical distances (in
Mb) given in UCSC Genome Browser (GRCh37/hg19 assem-
bly) considering 1 Mb ¼ 1cM.
The population growth rate (genr) in Northern-eastern
Italy was estimated with the following formula: genr ¼ log
Pt
P0
g in
which genr is the population growth rate per generation, Pt is
the estimated present population size, P0 is the estimated size
of the population at reference time and g is the number of
generations between these two time points. The total popula-
tion of the Veneto region and of the provinces of Pordenone
and Udine in Friuli currently comprises 5,737,630 people
(http://demo.istat.it/). Historical and demographic data indi-
cate that about 800,000 people lived in this area in year
1200.28 Accordingly, the average genr of this population was
estimated to be 0.0599 from 1200 to the present time, assum-
ing 25 years/generation. The latter value was used for muta-
tion age estimates.
The proportion of mutation bearing chromosomes
sampled was estimated to be 0.0677 and was calculated con-
sidering a population of 3,688,558 inhabitants living in the
area of the North-Eastern Italy from which the patients origi-
nated (provinces of Udine, Pordenone, Venezia, Rovigo, Ver-
ona, Treviso and Belluno), and assuming that the prevalence
of MAP (clinical plus subclinical biallelic carriers) is about
1:10,000 among Europeans.29
MUTYH mRNA analysis
Totally, 2–3 x 106 lymphoblastoid cells from five patients and
two controls were pelleted and RNA was extracted with the
EZ1 QIAgen RNA extraction Mini-kit (QIAgen, German-
town, MD). Genomic DNA contamination was avoided by
the addition of DNAse during the extraction phase. Reverse
transcription was performed using the Reverse Transcription
System kit (Promega, Madison, WI) on 1 lg of total RNA.
Quantitative analysis of MUTYH transcripts was per-
formed on cDNA by real-time duplex PCR, with home-made
and predeveloped TaqMan assays (Applied Biosystems) on aTa
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Biorad CFX 96 thermal cycler, using the TaqMan Gene
Expression Master Mix (Applied Biosystems). Three different
MUTYH TaqMan assays were designed and used for relative
quantification. MUTYH wild-type and mutated signals were
detected using two FAM-TAMRA probes, specific for exon
9-exon 10 and exon 9-exon 11 junctions, respectively. The
total amount of MUTYH mRNA (nuclear and mitochondrial
forms, normal and mutated) was detected with a predevel-
oped TaqMan Gene Expression Assay (Applied Biosystems)
containing a FAM-MGB probe directed at the junction
between exons 5 and 6. Each MUTYH assay signal was nor-
malized by quantitation of housekeeping genes in duplex
condition. Two different housekeeping genes (b-actin and
b-tubulin) were analyzed through predeveloped assays
containing a VIC-MGB probe (Applied Biosystems).
Quantitative evaluation was carried out by comparing the
mutated samples with the two WT controls by the DDCt
method.
Western blotting
Lymphoblastoid cells (5 x 106) were centrifuged to eliminate
the culture medium and washed once with PBS 1X. Pelleted
cells were then resuspended in lysis buffer (Tris-HCl 20 mM,
NaCl 100 mM, MgCl2 5 mM, EDTA 0.2 mM, NP40 0.1%)
containing protease and phosphatase inhibitors (Sigma,
St.Luis, MO) and incubated 30 min on ice. Lysed cells were
then centrifuged in a microfuge and the supernatant, contain-
ing whole cell protein extract, was collected in a new vial.
Protein concentration was determined by Bradford assay
(BioRad, Hercules, CA) and 50 lg of whole cell extracts were
analyzed by SDS-PAGE and western blotting. The primary
antibody used was a mouse monoclonal anti-MUTYH (Ab
55551; Abcam, Cambridge, UK) specific for a C-terminal
protein epitope (aa 435-535). The signal was amplified by an
HRP-conjugated secondary antibody and revealed by
Enhanced ChemiLuminescence (ECL; GE Healthcare, Little
Chalfont, UK). MUTYH signals were normalized using the
b-tubulin housekeeping protein (rabbit polyclonal anti-tubu-
lin b, Santa Cruz Biotechnology, Santa Cruz, CA).
Results were confirmed in three independent experiments
performed on LCL whole extracts produced in different
extraction sessions.
Statistical analyses
Allele frequency distributions in wild type and Italian
c.933þ3A>C chromosomes were compared by Fisher’s exact
tests; p < 0.01 was considered as a cut-off for statistical
significance.
Western blot and real-time PCR results are reported as
mean 6 SD of signals obtained in three experiments. Com-
parisons of expression levels between patient and control
samples were performed with a two-tailed paired Student’s t
test (*p < 0.05, **p < 0.01 and ***p < 0.001).
Results
Haplotype analysis and age estimation
To verify the presence of a possible founder effect, allele and
haplotype analyses were first performed on the 11 Italian
families segregating the c.933þ3A>C mutation and on 148
Italian control chromosomes (140 from the healthy control
individuals and 8 from noncarrier relatives in MAP families).
Statistically significant differences in allele frequencies
between control and c.933þ3A>C chromosomes were
observed at loci D1S211, D1S421, D1S451, D1S2677 and
D1S3175 (Table 2), the markers located closer to MUTYH,
strongly suggesting a founder effect.
Haplotype analysis using eight microsatellite markers
flanking the MUTYH locus was performed on probands and,
when possible, on additional family members. Five families/
individuals, including the c.933þ3A>C homozygote, shared
a common haplotype at loci D1S421, D1S451, D1S2677 and
D1S3175 (148-246-167-157) spanning a region of 0.8 Mb
(Table 3). This common haplotype was not found in control
chromosomes. In addition, although molecular analysis was
not completely informative for D1S451, the same haplotype
combination appeared to be the most likely in four additional
families/individuals (FAP82, FAP294, FAP117, FAP443).
In family CFS167, the D1S451 allele on the c.933þ3A>C
chromosome differs from that found in the other patients
investigated. This finding is compatible with either a recom-
bination event or a mutation that occurred in D1S451 on the
founder chromosome. Another possible recombination
between markers D1S2677 and D1S451 was observed in pro-
band FAP181; however, his haplotypes could not be defined
with certainty because no other family members were avail-
able for analysis.
Mutation age estimate based on DMLEþ2.2 software was
83 generations (95% credible set: 57–137) (Fig. 2), using
haplotype data from probands and controls.
In addition, haplotype analysis using eight microsatellites
was performed on eleven German probands and three family
members with the c.933þ3A>C mutation. Although segrega-
tion could not be investigated in detail, the allele combina-
tions observed in all probands, including two unrelated
homozygotes, were compatible with the shared Italian haplo-
type at loci D1S421, D1S451, D1S2677 and D1S3175 (148-
246-167-157) (Table 3).
MUTYH expression analyses
Analysis of splicing alteration showed that all samples with
c.933þ3A>C had exon 10 skipping and traces of additional
transcripts retaining intron 11, with and without exon 10,
which probably represent alternatively spliced isoforms (data
not shown). The full-length and skipped transcripts were
then quantified by real-time TaqMan PCR assays (Fig. 3a).
Mean results of three different experiments showed that all
c.933þ3A>C positive samples expressed equal or slightly
reduced amounts of total MUTYH transcripts (exons 5-6
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Table 3. Haplotype analysis in the families segregating the c.933þ3A>C MUTYH mutation
CASE ID1 D1S2861 D1S211 D1S421 D1S451 D1S2677 MUTYH D1S3175 D1S2797 D1S2874
FAP349 197/199 180 148 246 167 c.933þ3A>C 157 150/164 232
197/199 184 148 246 167 c.933þ3A>C 157 150/164 230
CFS443 199 180 148 246 167 c.933þ3A>C 157 150 232
197 184 148 252 167 c.1437delGGA 157 160 230
FAP352 195 180 148 246 167 c.933þ3A>C 157 150 230
199 174 148 252 159 WT 157 160 234
FAP278 197 180/184 148 246 167 c.933þ3A>C 157 150/164 228/230
195 180/184 148 252 167 c.1147delC 157 150/164 228/230
FAP426 197/199 166 148 246 167 c.933þ3A>C 157 172 230/232
197/199 168 146 252 167 c.536A>G 157 164 230/232
FAP 82 195 180/184 148 246/252 167 c.933þ3A>C 157 164 228/234
195 180/184 148 246/252 167 c.536A>G 157 164 228/234
FAP294 197/199 180/186 148 246/252 167 c.933þ3A>C 157 150/164 230/232
197/199 180/186 148 246/252 167 c.734G>A 157 150/164 230/232
FAP117 197/199 172/184 148 246/252 167 c.933þ3A>C 157 164/174 228
197/199 172/184 148 246/252 167 c.1437delGGA 157 164/174 228
FAP443 197/201 184 148 246/252 167 c.933þ3A>C 157 166/172 234/236
197/201 184 148 246/252 167 c.421delC 157 166/172 234/236
CFS167 197 164 148 248 167 c.933þ3A>C 157 164 230
199 170 148 252 167 c.1147delC 157 164 228
FAP181 199/201 180/182 148/146 250/252 167/159 c.933þ3A>C 157/161 160/164 230/238
199/201 180/182 148/146 250/252 167/159 c.1187G>A 157/161 160/164 230/238
16530 199 172 148 246 167 c.933þ3A>C 157 172 236/238
199 172 148 246 167 c.933þ3A>C 157 172 236/238
25045 197 186 148 246 167 c.933þ3A>C 157 172 238
197 186 148 246 167 c.933þ3A>C 157 172 238
354 197/203 168/186 148 246/252 167 c.933þ3A>C 157 164/172 234/238
197/203 168/186 148 246/252 167 c.1437delGGA 157 164/172 234/238
3345 197/199 170/186 148 246/252 167 c.933þ3A>C 157 168/172 228/232
197/199 170/186 148 246/252 167 c.536A>G 157 168/172 228/232
4017 199 168/186 148 246/252 167 c.933þ3A>C 157/161 164/172 232/238
199 168/186 148 246/252 167 c.536A>G 157/161 164/172 232/238
4022 197 174/184 148 246/252 167 c.933þ3A>C 157 164/166 228/230
197 174/184 148 246/252 167 c.536A>G 157 164/166 228/230
4704 195 170/186 148 246/252 167 c.933þ3A>C 157 164/172 230/238
195 170/186 148 246/252 167 c.536A>G 157 164/172 230/238
5537 197/199 172/184 148 246/252 167 c.933þ3A>C 157 164/172 230/238
197/199 172/184 148 246/252 167 c.536A>G 157 164/172 230/238
12287 197 184 148 246/252 167 c.933þ3A>C 157/161 166/172 228/238
197 184 148 246/252 167 c.536A>G 157/161 166/172 228/238
17203 197/199 172/184 148 246/252 167 c.933þ3A>C 157 172 228/238
197/199 172/184 148 246/252 167 c.536A>G 157 172 228/238
30457 199 166/184 148 246/252 167 c.933þ3A>C 157 166 234
199 166/184 148 246/252 167 c.536A>G 157 166 234
Numbers indicate the alleles observed on each chromosome of Italian (upper part) and German (lower part) families.
The ‘‘/’’ symbol indicates that the phase of the disease haplotype could not be established.
Alleles present in the shared haplotype are represented in bold type.
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probe) compared to controls. In addition, based on the exon
9-10-specific assay, all mutated samples had a level of tran-
script containing exon 10 significantly lower compared to
controls (<50%). Interestingly, we observed that the homozy-
gote for c.933þ3A>C produces traces of correctly spliced
MUTYH transcript (about 10% of the total amount). To inte-
grate data of the exon 9-10 assay, we also quantified
c.933þ3A>C transcripts lacking exon 10 using an exon 9-
exon 11 probe. As expected, both WT samples were negative
for this assay, whereas all LCLs from compound heterozy-
gotes expressed the exon 10 transcript, in amounts lower
than 50% compared to the FAP349 homozygote.
FAP349 expressed traces of full-length protein, whereas
compound heterozygous LCLs expressed variable amounts of
MUTYH, ranging from 1 to 90% of the WT signal, depend-
ing on the nature of the second mutation and on the affinity
of the primary antibody used that fails to recognize C-termi-
nal truncated protein products (Fig. 3b).
Figure 2. Posterior probability distribution plot of the c.933þ3A>C
mutation age (in generations), as estimated by DMLEþ2.2 software
(genr ¼ 0.0599). The vertical broken lines indicate the 95%
credible set of value for the calculation. Peak: 83 generations
(95% credible set 57–137).
Figure 3. Quantitation of MUTYH gene and protein expression in LCLs (a) mRNA expression analysis by real-time PCR. Graphs report the
mean ratio of MUTYH exon 5–6, 9–10 and 9–11 assay signals normalized by b-tubulin and b-actin genes (mean of three experiments with
standard deviations). Control bars are WT (mean results obtained on two wild-type LCLs) for the 5–6 and 9–10 assays, FAP349
(c.933þ3A>C homozygote) for the 9–11 assay. An assay scheme is reported below each graph (P, probe; FW, forward primer; REV, reverse
primer). *p < 0.05 and **p < 0.01 relative to controls. (b) Western blot analysis of MUTYH protein. Bars with standard deviations represent
the mean ratio between MUTYH and b-tubulin for three experiments on each sample. **p < 0.01 and ***p < 0.001 relative to WT controls.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Discussion
During the last 8 years the functional effects of different
MUTYH mutations have been characterized,30–34 and the
results of mutation analyses have revealed the existence of
ethnic differences in the distribution of MUTYH variants.7,8
However, so far, founder effects have not been documented
for MUTYH variants.
The c.933þ3A>C mutation is frequently found in patients
from the North-East of Italy. It involves the 3rd base of
intron 10, altering the consensus sequence of the donor splice
site. Skipping of exon 10 with insertion of a premature stop
codon has been documented.21 The LOVD database reports
the predicted effect on the protein as p.Gly264TrpfsX7.14 In
our cohort of patients, it accounted for about 15% of all
MUTYH mutations so far identified. c.933þ3A>C is present
in other populations, although its proportion among MUTYH
mutations has been found to be lower (1–8%) in studies on
Caucasian patients from North America and other European
countries.7,9,15–26 In particular, it has been identified in sev-
eral German and in a few Swiss patients (LOVD).
In this study, we identified a common haplotype spanning
a region of approximately 0.8 Mb surrounding the MUTYH
gene, in North–Eastern Italian and German families segregat-
ing the c.933þ3A>C. According to the DMLEþ2.2 software,
the age of the MUTYH c.933þ3A>C mutation was estimated
as 83 generations (95% credible set: 57–137), corresponding
to 2,075 (95% credible set: 1,425–3,425) years. Therefore its
origin in North-Eastern Italy should date back to when the
Venetics (Venetian population) lived in this area. However, it
is worth noting that the method used estimates the time of
origin of the mutation and not the time from the most recent
common ancestor in Italy.35 In addition, the results obtained
with the DMLE, like with other Bayesian methods for the
determination of age of mutation origin or age of the most
recent common ancestor, are influenced by the input param-
eters used, namely the genr value. The genr used in this study
was calculated based on the most reliable historical estimates
of population size that are available for North-Eastern Italy.
The evidence that the Italian and German c.933þ3A>C
chromosomes share the same haplotype suggests that this
mutation has originated only once in the past, at least in
Europe. From available data it cannot be determined if the
c.933þ3A>C originated in Italy and then spread to other
areas where it is now found at appreciable frequencies, or
alternatively, if it entered in the Italian population from
somewhere else, possibly Germany, and then became fre-
quent in Italy. This issue could possibly be solved when data
on the c.933þ3A>C frequency in different parts of Europe
will become available.
Analyses of mRNA extracted from LCLs confirmed the
presence of transcripts lacking exon 10 in 5 patients with the
c.933þ3A>C mutation (1 homozygote and 4 compound het-
erozygotes). This aberrant mRNA, if translated, determines
the synthesis of a truncated protein lacking a nuclear local-
ization signal and the binding site for APE1 (human Apur-
inic/Apyrimidinic Endonuclease) and PCNA (Proliferating
Cells Nuclear Antigen). A MUTYH protein devoid of these
functional domains most likely would lose nuclear localiza-
tion and DNA repair activity. As previously described for
c.934-2A>G,30 the truncated MUTYH protein could accumu-
late in the cytoplasm.
A real-time quantitative assay for MUTYH transcripts was
set up to compare transcript levels between patients and con-
trols and to measure the proportion of altered transcript on
the total amount of MUTYH mRNA produced. Results
showed that the overall levels of MUTYH transcript were
equal, or slightly lower, in all c.933þ3A>C LCLs compared
to WT controls. As expected, all c.933þ3A>C samples had
significantly lower levels of correctly spliced transcript in
comparison with controls. Interestingly, also the FAP349 LCL
homozygous for c.933þ3A>C revealed traces of normal tran-
script. This finding indicates that a very small amount of
transcript produced from mutant alleles can be correctly
spliced, generating traces of full-length functional protein, as
revealed by Western blot analysis. Quantitative real-time
analysis confirmed the presence of significantly lower
amounts of exon 10 transcripts in heterozygotes compared
to FAP349, and that WT LCLs did not produce the aber-
rantly spliced transcript.
Protein amounts produced by LCLs with the
c.933þ3A>C mutation ranged between 1 and 100% of WT
LCLs. This wide variability was dependent on the effects of
the second mutation. The homozygous mutant gave less than
10% of WT signal. When the second mutation event caused
another frameshift with insertion of a premature stop codon
(c.1147delC in FAP278), no significant signal was observed,
according to the predicted loss of MUTYH C-terminal target
epitope for the antibody used in this study. On the other
hand, when the second mutation event determined loss
(FAP117) or substitution (FAP181 and FAP294) of a single
aminoacid, protein band intensities were variable. FAP117
and FAP294 express about 50% of the MUTYH protein levels
observed in WT cells; likely, the c.1437delGGA (p.Glu480del)
and c.734G>A (p.Arg245Hys) alleles present in these LCLs
are able to drive the synthesis of almost normal protein
amounts, indicating that these mutations do not grossly affect
mRNA or protein stability. Instead, the compound heterozy-
gote FAP181 containing c.1187G>A (p.Gly396Asp) expresses
protein amounts equal to WT, suggesting that the produced
protein is stable but not functional, in accordance with previ-
ous findings.31 Unfortunately, the lack of reliable antibodies
directed against the N-terminus of MUTYH prevented us to
investigate the expression and stability of the putatively trun-
cated protein. However, if the c.933þ3A>C encoded a trun-
cated p.Gly264TrpfsX7 protein, this would likely not be func-
tional due to the loss of nuclear localization and impaired
binding to key components of DNA repair.
On the basis of these findings, subjects carrying a homo-
zygous MUTYH c.933þ3A>C mutation should have a
reduced ability to correct nuclear DNA damages induced by
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reactive oxygen species in their colon mucosa, and this would
increase the risk of adenomas and CRC. The extent of risk in
compound heterozygotes is likely to be dependent on the
effects of the second mutation. Almost all c.933þ3A>C car-
riers in our series had an attenuated form of polyposis, the
most common phenotype in MAP patients.9 Interestingly, the
homozygous FAP349 patient underwent hemicolectomy
following a diagnosis of attenuated polyposis (less than 30
polyps) at 51 years, in absence of CRC. Conversely, CRC was
diagnosed before 55 years of age in 7 of the other 11 com-
pound heterozygotes. The observation that traces of full-
length transcripts and proteins are expressed in c.933þ3A>C
LCLs suggest that the mutant allele maintains a minimal
residual MUTYH function, thus producing an attenuated
phenotype. On the other hand, it has been observed that
mutations that completely inactivate the MUTYH protein,
such as frameshift variants and the Caucasian p.Tyr179Cys
mutation, are usually associated with a more severe
phenotype.9
The molecular and clinical data obtained in this study and
the demonstration of a founder effect for c.933þ3A>C have
implications for MUTYH genetic testing. To optimize
MUTYH mutation analysis, a rapid screening for
c.933þ3A>C and for the two most common Caucasian
mutations (p.Gly396Asp and p.Tyr179Cys) could be under-
taken as a first step for molecular analysis in polyposis
patients of ascertained North-Eastern Italy ancestry. Since al-
together these three mutations account for almost 60% of the
MUTYH alterations detected in this area, a simple multiplex
ad hoc test would allow to rapidly establish a genetic diagno-
sis of MAP in at least one third of patients with this condi-
tion. Moreover, this test could be also applied for genetic pre-
screening of polyposis/CRC patients not fully complying with
current criteria for referral to MUTYH genetic testing. In
addition, the data here presented suggest that genotype
knowledge may be useful for phenotype prediction and con-
sequently to establish tailored surveillance. However, evalua-
tion of larger series will be necessary to allow a better defini-
tion of genotype/phenotype correlations, in order to optimize
surveillance in at risk individuals.
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